CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 384 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Olanzapine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05676294
NCT05676294Phase 2Completed

The Impact of Pre-operative Olanzapine on Quality of Recovery-40 Scores After Discharge From Ambulatory Surgery

Yale University·interventional·Posted Jan 9, 2023·Updated Dec 15, 2025

In Brief

A Phase 2 clinical trial evaluating Olanzapine and Placebo for Postoperative Nausea and Vomiting. Completed, enrolled 384 participants across 1 site.

Detailed Summary

The primary objective of this phase 2 randomized controlled trial is to determine whether the pre-operative administration of olanzapine (5 mg PO) improves quality of recovery (assessed by the Quality of Recovery-40 (QoR-40) survey) on postoperative day 1 in patients having ambulatory surgery with general anesthesia. The secondary objectives of this study are to determine whether there are differences in quality of recovery on postoperative day 2, presence of post-discharge nausea, presence of severe post-discharge nausea, recovery room length of stay and opioid consumption in patients who receive the study drug versus placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJan 9, 2023
Enrollment StartJun 26, 2023
Primary CompletionDec 5, 2025
Study CompletionDec 6, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.5 years ago

Interventions

Olanzapinedrug

5 mg of oral olanzapine one hour prior to ambulatory surgery

Placebodrug

oral matched placebo one hour prior to ambulatory surgery